In this study, we investigated whether Oxy ameliorates Aβ31‐35‐induced circadian rhythm disorders and identified the role of GLP‐1R using lentiviral vectors that interfere GLP‐1R expression both in vivo and in vitro to provide a novel therapeutic target for the treatment of AD. Here, GLP1R is linked to Alzheimer disease.